PDE4A and chronic obstructive pulmonary disease: Overall, AWD12-281 was a selective PDE4 inhibitor (IC50 = 9.7 nM), suitable for administration via dry powder drug inhalation [67], being therefore evaluated in clinical trials for the treatment of lung inflammatory diseases, primarily COPD.